Novel Therapy for Male Hypogonadism
Purpose of Review
Hypogonadism and the treatment of low testosterone is increasingly a subject of medical inquiry and controversy. The few treatments that are FDA-approved such as testosterone topicals, injections, and pellets create significant demand from patients for treatments with more convenient means of administration, fewer adverse effects, and the ability to maintain male fertility. Off-label drugs are in abundant use for low testosterone, including selective estrogen receptor modulators, gonadotropins, and aromatase inhibitors.
In this review, we summarize the evidence in support of commonly used treatments for male hypogonadism, as well as discuss recent updates in the development of novel therapeutics.
New therapies include nasal testosterone, new oral testosterone formulations, anabolic-androgenic steroids, and selective androgen receptor modulators.
KeywordsHypogonadism Testosterone Testosterone replacement therapy SARM Clomiphene
Compliance with Ethical Standards
Conflict of Interest
Robert Carrasquillo and Kevin Chu each declare no potential conflicts of interest.
Ranjith Ramasamy is the lead investigator on clinical trials for use of Natesto in treatment of hypogonadism with Aytu BioScience (ClinicalTrials.gov Identifier NCT03203681).
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as:• Of importance
- 11.• DiGiorgio L, Sadeghi-Nejad H. Off label therapies for testosterone replacement. Transl Androl Urol. 2016;5(6):844–9. This study summarizes key off-label treatments for hypogonadism, highlighting the importance of treatments that preserve fertility such as SERMs. CrossRefPubMedPubMedCentralGoogle Scholar
- 18.• Vignera SL, Condorelli RA, Cimino L, Russo GI, Morgia G, Calogero AE. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. Aging Male. 2015;19(1):34–9. This study brings to light the use of hCG as an alternative to testosterone therapy. It may allow for the alleviation of symptoms by maintaining more physiologic levels of endogenous testosterone with fewer side effects. CrossRefPubMedGoogle Scholar
- 25.Wynia B, Kamintsky JC. Current and emerging testosterone therapies for male hypogonadism. Res Rep Endocr Disord. 2015;5:59–69.Google Scholar
- 26.Ceponis J, Yadav P, Swerdloff RS, Wang C. Chapter 11: Testosterone therapy: transdermal androgens. Testosterone: from basic to clinical aspects. Springer, 2017.Google Scholar
- 27.Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossi-Gerning N, David J, Muneer, A. British society for sexual medicine guide-lines on adult testosterone deficiency, with statements for UK practice. J Sex Med. 2017;14(12):1504–23.Google Scholar
- 29.ANDRODERM (testosterone patch) [prescribing information]. Watson Pharma, Inc. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020489s025lbl.pdf. Accessed 13 March 2018.
- 36.Testopel (testosterone pellets). prescribing information. Rye: Slate pharmaceuticals, Inc.; 2013.Google Scholar
- 41.• Conners W, Morgentaler A, Guidry M, Westfield G, Bryson N, Goldstein I. Proceedings of the American Urological Association Annual Meeting. J Urol. 2017;197 Supp 4S; Poster MP89–06. Online at: http://www.jurology.com/article/S0022-5347(17)61534270-2/pdf. Accessed 13 March 2018. This study represents preliminary findings suggestive that nasal testosterone may allow for treatment of hypogonadism with fertility preservation. Confirmatory clinical trials are now underway.
- 50.Ault A. FDA panel votes down oral testosterone replacement products. Medscape News. 2018. Accessed: 2018 Feb 24. Online at: https://www.medscape.com/viewarticle/891186?src=rss#vp_1.
- 51.US Drug Enforcement Agency. Designer anabolic steroid control act of 2014. https://www.cbo.gov/publication/45595. Accessed 13 March 2018.
- 53.• Wu C, Kovac JR. Novel uses for the anabolic androgenic steroids nandrolone and oxandrolone in the management of male health. Curr Urol Rep. 2016;17(10):72. This review summarizes data regarding anabolic steroids that suggests they may be of benefit in hypogonadal men from their more potent myotrophic qualities. CrossRefPubMedGoogle Scholar
- 60.Häkkinen K, Kraemer WJ, Pakarinen A, Triplett-McBride T, McBride JM, Häkkinen A, et al. Effects of heavy resistance/power training on maximal strength, muscle morphology, and hormonal response patterns in 60-75-year-old men and women. Can J Appl Physiol. 2002;27(3):213–31.CrossRefPubMedGoogle Scholar